Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

MetronomIc CApecitabine and DOcetaxel as Second-line Chemotherapy for Advanced Gastric Cancer Patients Previously Treated With Fluoropyrimidine and Platinum Agents MiCADO Study

NCT02007148 is registered in ClinicalTrials.gov with International Group of Endovascular Oncology as lead sponsor.

NCT NCT02007148
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02007148 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
MetronomIc CApecitabine and DOcetaxel as Second-line Chemotherapy for Advanced Gastric Cancer Patients Previously Treated With Fluoropyrimidine and Platinum Agents MiCADO Study
Lead sponsor
International Group of Endovascular Oncology
Phase
Phase 2
Overall status
Unknown status
Start date
November 30, 2013
Completion date
May 31, 2022
Enrollment
51 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

gastric adenocarcinoma, gastroesophageal junction adenocarcinoma